Compare Inovio Pharmaceuticals Inc (INO) vs iShares Semiconductor ETF (SOXX) Price & Performance

INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.

The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.

SOXX trades at $524.14, up 0.45% with a bearish technical signal from moving averages. The semiconductor ETF faces volatility amid AI sector rotation, with RSI levels below 30 suggesting potential oversold conditions. Recent news highlights semiconductor leadership in market rebounds but also bear market concerns, with the ETF down 20% from June highs. Support levels cluster around $518-$512, while resistance begins at $529.

Outlook remains cautious due to sector concentration risks and cyclical pressures, though oversold technicals may offer near-term bounce potential. Key risks include AI trade volatility, China export controls, and hyperscaler capex pressures. Analyst views are mixed, with some highlighting long-term growth prospects despite recent underperformance.